OGeS has developed a broad pipeline of both therapeutic antibodies and diagnostics in the field of cancer based
on its strategic collaborations with Medarex Inc. and Biosite Inc.
Therapeutic Antibody Pipeline
OGeS’ most advanced therapeutic antibody programmes are developed in collaboration with Medarex on a 50:50 cost
and profit share basis. The lead programmes target a number of solid cancer indications including colorectal
cancer and are expected to produce several clinical development candidates in 2008. OGeS is developing a companion
diagnostic for several of these programmes in collaboration with Biosite.
OGeS has obtained broad access to Medarex’s fully human antibody technology with the aim of accelerating the development
of its own pipeline of novel antibodies in the field of cancer. Under the terms of the agreement, OGeS will retain full
worldwide rights to the antibodies. In parallel, to further accelerate its pipeline development, OGeS has established
a three-way agreement with Biosite and Medarex. Medarex will provide access to its transgenic
technology to Biosite, and Biosite will carry out the early stage antibody generation on behalf of OGeS for a potentially
large number of OGeS’ antibody programs. This is partly in exchange for Biosite receiving access to the OGeS diagnostic
targets in colorectal and ovarian cancer. This arrangement is expected to improve OGeS’ productivity and put top quality
antibody therapeutic programs into development more quickly.
OGeS has
identified a number of cancer targets from its OGAP® database, five of which are now being prepared to enter the
preclinical development phase. OGeS has identified another 15 targets that will also be committed to the same pipeline.
In addition, under a separate agreement between OGeS and Biosite, Biosite will establish a companion diagnostic
assay on certain programs selected by Biosite and OGeS. This provides OGeS with the opportunity to create a significant
portfolio of personalised cancer therapeutics with companion diagnostics for many of its oncology targets.
Diagnostic Pipeline
OGeS in collaboration with Biosite has built a promising pipeline of blood-based cancer diagnostics for the
diagnosis and prognosis of colorectal and ovarian cancer. Under the terms of the collaboration, novel diagnostic markers
identified by OGeS through OGAP
® will be developed by Biosite into blood-based diagnostic products.
OGeS will receive research milestone payments and royalties. The most advanced diagnostic programme is for
colorectal cancer and is currently in clinical evaluation. OGeS and Biosite initiated a second diagnostic
programme for ovarian cancer in 2007.
